Johnson Investment Counsel Inc. Sells 1,100 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Johnson Investment Counsel Inc. trimmed its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 5.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,790 shares of the specialty pharmaceutical company’s stock after selling 1,100 shares during the period. Johnson Investment Counsel Inc.’s holdings in Jazz Pharmaceuticals were worth $2,437,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. CIBC Asset Management Inc grew its holdings in shares of Jazz Pharmaceuticals by 5.2% in the 4th quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company’s stock valued at $243,000 after acquiring an additional 97 shares in the last quarter. UMB Bank n.a. grew its holdings in shares of Jazz Pharmaceuticals by 70.9% in the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after acquiring an additional 129 shares in the last quarter. Jones Financial Companies Lllp grew its holdings in shares of Jazz Pharmaceuticals by 75.1% in the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock valued at $37,000 after acquiring an additional 130 shares in the last quarter. Waterfront Wealth Inc. grew its holdings in shares of Jazz Pharmaceuticals by 1.4% in the 4th quarter. Waterfront Wealth Inc. now owns 9,675 shares of the specialty pharmaceutical company’s stock valued at $1,191,000 after acquiring an additional 137 shares in the last quarter. Finally, Ellsworth Advisors LLC grew its holdings in shares of Jazz Pharmaceuticals by 0.4% in the 4th quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company’s stock valued at $4,675,000 after acquiring an additional 149 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CAO Patricia Carr sold 4,813 shares of the firm’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.42, for a total transaction of $695,093.46. Following the transaction, the chief accounting officer now directly owns 8,237 shares of the company’s stock, valued at approximately $1,189,587.54. This trade represents a 36.88 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. Following the transaction, the chief executive officer now directly owns 425,525 shares in the company, valued at approximately $52,522,550.75. This represents a 0.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 26,333 shares of company stock valued at $3,690,226. Company insiders own 4.20% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on JAZZ. Morgan Stanley restated an “overweight” rating and issued a $183.00 price objective (up previously from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. HC Wainwright upped their target price on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a “buy” rating in a report on Monday. Needham & Company LLC reaffirmed a “buy” rating and issued a $210.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, March 5th. Robert W. Baird upped their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a report on Monday, November 18th. Finally, Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and upped their target price for the company from $140.00 to $150.00 in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $190.53.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $136.86 on Wednesday. The company has a market capitalization of $8.31 billion, a price-to-earnings ratio of 19.28, a PEG ratio of 1.04 and a beta of 0.44. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The company has a 50-day simple moving average of $128.70 and a 200 day simple moving average of $120.40. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $148.06.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.